May 18 (Reuters) - The U.S. Food and Drug Administration on
Wednesday granted accelerated approval for Roche Holding AG's
immunotherapy for the most common form of bladder
cancer, marking the company's entry into a lucrative class of
drugs.
Read more
No comments:
Post a Comment